Table 1.
Drug | GPA Precursor | Microbiological Spectrum | Main Clinical Indication | Status |
---|---|---|---|---|
Oritavancin (Orbactiv) | Chloroeremomycin | MRSA 1, VRSA 1, VRE 1 | ABSSSI 2 | approved by FDA 3 in 2014 |
Telavancin (Vibativ) | Vancomycin | MRSA 1, MSSA 1, VSE 1, Streptococcus pyogenes | cSSSI 2 | approved by FDA 3 in 2009 |
Staphylococcus aureus | HABP/VABP 2 | approved by FDA 3 in 2013 | ||
Dalbavancin (Dalvance) | A40926 | MRSA 1, MSSA 1, Streptococcus pyogenes | ABSSSI 2 | approved by FDA 3 in 2014 |
1 MRSA, methicillin-resistant Staphylococcus aureus; VRSA, vancomycin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; MSSA, methicillin-susceptible Staphylococcus aureus; VSE, vancomycin-susceptible enterococci; 2 ABSSSI, acute bacterial skin and skin structure infections; cSSSI, complicated skin and skin structure infections; HABP/VABP, hospital-acquired and ventilator-associated bacterial pneumonia; 3 FDA, Food and Drug Administration.